Ezrin、E-cadherin在鼻咽癌组织中的表达及临床意义
摘要
目的:检测鼻咽癌组织中埃兹蛋白(Ezrin)及上皮细胞钙黏蛋白(E-cadherin)的表达情况,探讨他们与肿瘤侵袭、转移及预后的关系,以及两者的相关性。
材料与方法:收集临床确诊的存档鼻咽低分化鳞癌石蜡标本42例,将每个标本的4张切片分别进行HE染色、免疫组化SP法及阴性对照。HE确认病理类型,结合临床资料进行TNM分期,根据IHC染色结果检测Ezrin及E-cadherin的表达,同时对所选病例进行随访。所得结果用SPSS16.0进行统计学检验。
结果:Ezrin呈阳性表达在鼻咽炎性标本上皮细胞中只有1例(1/10),鼻咽癌组织中28例(28/42),阳性信号沿细胞膜内侧线性分布,也有部分在胞浆呈棕色颗粒分布;Ezrin的表达与鼻咽癌的T分期(p=0.001)、淋巴结转移(p=0.015)、临床分期(p=0.028)显著相关;与鼻咽癌的性别、年龄无明显相关;而E-cadherin在鼻咽癌组织中呈不同程度的降低(P＜0.01),与性别、年龄无明显相关;与T分期(p=0.023)、淋巴结转移(p=0.039)、分期(p=0.003)显著相关;经Spearman相关分析,Ezrin与E-ceadherin在鼻咽癌组织中的表达呈明显负相关(r=-0.450,P＜0.05);生存分析提示Ezrin阳性表达、肿瘤TNM分期、E-cadherin表达下调及有淋巴结转移者与生存率有关。
结论:1.Ezrin表达升高及E-cadherin的表达减弱或丢失与鼻咽癌临床分期、淋巴结转移有关,可作为鼻咽癌重要的恶性生物学指标之一。
2.Ezrin及E-cadherin在鼻咽癌组织中的表达呈明显的负相关。
3.联合检测Ezrin、E-cadherin的表达水平,可能为鼻咽癌预后判断提供依据。
Objective To investigate the expression of Ezrin and E-cadherin ,as well as their correlations with the invasion and metastasis of nasopharyngeal carcinoma.
Materials and Methods 42 cases of nasopharyngeal poorly differentiated squamous cell carcinoma were selected, each of the four sections specimens were HE staining, immunohistochemical sp method and negative control. According to the staining results of the expression of Ezrin and E-cadherin, while follow-up of the selected cases .The results of statistical rests conducted by spss 16.0.
Results Ezrin was positive expression only in one of 10 cases of chronic nasopharyngitis (1/10),but 28 cases of positive expression(28/42) in nasophyaryngeal carcinoma,positive signal linearity distributed along the inside of cell membrane ,as well as some in the cytolymph as brown slurry particle. Ezrin expression was closed corrected with depth of invasion(p=0.001) ,lymph node metastasis(p=0.015)and TNM stage(p=0.028),not with gender and age; and E-cadherin was decreased or completely loss in nasopharyngeal carcinoma (P <0.01),and was closed corrected with depth of invasion(p=0.023) ,lymph node metastasis(p=0.039)and TNM stage(p=0.003),not with gender and age; by Spearman correlation analysis, Ezrin and E-cadherin in nasopharyngeal carcinoma expression was negatively correlated (r =- 0.450, P <0.01); survival analysis showed that positive expression of Ezrin, tumor TNM staging,decreased of E-cadherin expression were associated with survival rate of post-operation.
CONCLUSIONS
1. Excess expression of Ezrin protein and E-cadherin expression weakened or lost is closely related to primary tumor of invasion, TNM stage, lymph node metastasis, which suggested that the high expression of Ezrin protein may play an important role in development, invasion and metastasis of nasopharyngeal cancer.
2. The relationship of Ezrin and E-cadherin in nasopharyngeal carcinoma is significantly negative correlation.
3. Combined detection can be used as a valid set of tumor marker and prognostic indicator of nasopharyngeal carcinoma , and they can be used as biological signs to assess recurrence risk of patients with nasopharyngeal carcinoma.
材料与方法:收集临床确诊的存档鼻咽低分化鳞癌石蜡标本42例,将每个标本的4张切片分别进行HE染色、免疫组化SP法及阴性对照。HE确认病理类型,结合临床资料进行TNM分期,根据IHC染色结果检测Ezrin及E-cadherin的表达,同时对所选病例进行随访。所得结果用SPSS16.0进行统计学检验。
结果:Ezrin呈阳性表达在鼻咽炎性标本上皮细胞中只有1例(1/10),鼻咽癌组织中28例(28/42),阳性信号沿细胞膜内侧线性分布,也有部分在胞浆呈棕色颗粒分布;Ezrin的表达与鼻咽癌的T分期(p=0.001)、淋巴结转移(p=0.015)、临床分期(p=0.028)显著相关;与鼻咽癌的性别、年龄无明显相关;而E-cadherin在鼻咽癌组织中呈不同程度的降低(P＜0.01),与性别、年龄无明显相关;与T分期(p=0.023)、淋巴结转移(p=0.039)、分期(p=0.003)显著相关;经Spearman相关分析,Ezrin与E-ceadherin在鼻咽癌组织中的表达呈明显负相关(r=-0.450,P＜0.05);生存分析提示Ezrin阳性表达、肿瘤TNM分期、E-cadherin表达下调及有淋巴结转移者与生存率有关。
结论:1.Ezrin表达升高及E-cadherin的表达减弱或丢失与鼻咽癌临床分期、淋巴结转移有关,可作为鼻咽癌重要的恶性生物学指标之一。
2.Ezrin及E-cadherin在鼻咽癌组织中的表达呈明显的负相关。
3.联合检测Ezrin、E-cadherin的表达水平,可能为鼻咽癌预后判断提供依据。
Objective To investigate the expression of Ezrin and E-cadherin ,as well as their correlations with the invasion and metastasis of nasopharyngeal carcinoma.
Materials and Methods 42 cases of nasopharyngeal poorly differentiated squamous cell carcinoma were selected, each of the four sections specimens were HE staining, immunohistochemical sp method and negative control. According to the staining results of the expression of Ezrin and E-cadherin, while follow-up of the selected cases .The results of statistical rests conducted by spss 16.0.
Results Ezrin was positive expression only in one of 10 cases of chronic nasopharyngitis (1/10),but 28 cases of positive expression(28/42) in nasophyaryngeal carcinoma,positive signal linearity distributed along the inside of cell membrane ,as well as some in the cytolymph as brown slurry particle. Ezrin expression was closed corrected with depth of invasion(p=0.001) ,lymph node metastasis(p=0.015)and TNM stage(p=0.028),not with gender and age; and E-cadherin was decreased or completely loss in nasopharyngeal carcinoma (P <0.01),and was closed corrected with depth of invasion(p=0.023) ,lymph node metastasis(p=0.039)and TNM stage(p=0.003),not with gender and age; by Spearman correlation analysis, Ezrin and E-cadherin in nasopharyngeal carcinoma expression was negatively correlated (r =- 0.450, P <0.01); survival analysis showed that positive expression of Ezrin, tumor TNM staging,decreased of E-cadherin expression were associated with survival rate of post-operation.
CONCLUSIONS
1. Excess expression of Ezrin protein and E-cadherin expression weakened or lost is closely related to primary tumor of invasion, TNM stage, lymph node metastasis, which suggested that the high expression of Ezrin protein may play an important role in development, invasion and metastasis of nasopharyngeal cancer.
2. The relationship of Ezrin and E-cadherin in nasopharyngeal carcinoma is significantly negative correlation.
3. Combined detection can be used as a valid set of tumor marker and prognostic indicator of nasopharyngeal carcinoma , and they can be used as biological signs to assess recurrence risk of patients with nasopharyngeal carcinoma.
引文
[1]Tao Y,Bidault F,Bosq J,Bourhis J.Distant metastasis of undifferentiated carcinoma of nasopharyngeal type.Onkologie.2008 Nov;31(11):574-575.
[2]Bussemakers MJG,Bokhoven AV,Mees SGM,et al.Molecular cloning and characterization of the human E-cadherin cDNA[J].Mol Biol Rep,1993,17:123.
[3]Chou J,Lin YC,et,Kim J,Nasopharyngeal carcinoma—review of the molecular mechanisms of tumorigenesis.Head Neck.2008 Jul;30(7):946-63.
[4]Musial J,Sporny S,Nowicki A.Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer.Pol J Pathol.2007;58(4):235-243.
[5]YuY,Khan J,KhannaC,eta.l Expression profiling identifies the cytoskeletal organizer ezrin and the developmental hemeoprotein sixl as key metastatic regulators[J].NatMed,2004,10:175-181.
[6]MeClatehey Al.Merlin and ERM proteins:unappreciated roles in cancer development?Nat Rev Cancer 2003;3:877-883.
[7]HannaC,WanX,BoseS,CassadayR,Olomu0,MendozaA,YeungC,GorliekR,HewittSM,HelmanLJ.The membranecytoskeleton linker ezrin is necessary for osteosarcozna metastasis.Nat Med2004;10:182-186.
[8]Bruce B,Khanna G,et at,Expression of the cytoskeleton linker protein ezrin in human cancers.Clin Exp Metastasis.2007;24(2):69-78.
[9]Slater M,Cooper M,Murphy CR.The cytoskeletal proteins alpha-actinin,Ezrin,and talin are De-expressed in endometriosis and endometrioid carcinoma compared with normal uterine epithelium.Appl Immunohistochem Mol Morphol.2007;15(2):170-174.
[10]ValdrnanA,Fangx,PangST,NilssonB,EkmanP,EgevadL.Ezrin expression in prostate cancer and begian prostatic tissue.Eur Urol 2005;48:852-857.
[11]Federici C,Brambilla D,et,at,Pleiotropic function of ezrin in human metastatic melanomas.Int J Cancer,2009;124(12):2804-2812.
[12] Li Q, Wu M, et,Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells. Cancer Lett. 2008 ,261(1):55-63.
[13] Bornman D M, Mathew S, Alsrnhe J, et al. Methylation of the E-cadherin gene bladder neop lasia and in normal u rothelial expression from elderly individuals [J].Am J Pathol,2001,159(3):831-835.
[14] Gonzalea M A, Pinder S E, Wencyk P M, et al. An immunohistochemical examination of the expression of Ecadherin,aand p7y-catenins, and a2 and (31 integrins in invasive breast cancer [ J]. J Pathol, 1999, 187 ( 5): 523 -529.
[15] Vaheri A, Carpen O, Heiska L, et al. The ezrin protein family:membrane-cytoskeleton intevactions and disease associations [J].Curr Opin Cell Biol, 1997, 9(5): 659- 666.
[16] Smith W J, Nassar N, Bretscher A, et al. Andrew Karplus. Structure of the Active N- terminal Domain of Ezrin[J]. J Biol Chem, 2003, 278(7): 4949- 4956.
[17] Osawa H, Smith CA,et,at, The role of the membrane cytoskeleton crosslinker ezrin in medulloblastoma cells.Neuro Oncol. 2008,10(2): 175- 256.
[18] Poullet P, Gautreau A, Kadare G, et al. Ezrin Interacts with Focal Adhesion Kinase and Induces Its Activation Independently of Cellmatrix Adhesion[J]. J Biol Chen, 2001, 276 (40): 37686- 37691.
[19] Yu Y, Khan J, Khanna C, et al. Expression profilingidentifies thecytoskeletal organizer ezrin and thedevelopmental homeoprotein Six las key metastatic regulators [J]. Nat Med, 2004,10(2): 175- 256.
[20] Thorne R F, Legg J W, Isacke C M. The role of the CD44 transmembrane and cytoplasmic domains in co- ordinated adhesive and signaling Events[J]. JCell Sci, 2004,117(3): 373-380.
[21] Fievet BT, Gautreau A, Roy C, et al. Phosphoinositide binding and phosphorylation act sequentially in the activation mechanism of ezrin[J]. J Cell Biol, 2004, 164(5): 653-659.
[22] Martin T A, Harrison G, Mansel R E, et al. The role of the CD44/ezrin complex in cancer metastasis [J]. Crit Rev Oncol Hematol,2003,46(2): 165- 186.
[23] McClatchey A I. Merlin and ERM proteins: unappreciatedroles in cancer development[J].Cancer,2003,3(11):877-884.
[24]Federici C,Brambilla D,et,at,Pleiotropic function of ezrin in human metastatic melanomas.Int J Cancer.2009 Jun 15;124(12):2804-12.
[25]Kobel M,Langhammer T,Huttelmaier S,et al.Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas[J].Mod Pathol,2006,19(4):581-587.
[26]Weng WH,Ahlen J,Astrom K,et al.Prognostic impact of immunohistochemical expression of ezrin in highly malignant softtissue sarcomas[J].Clin Cancer Res,2005,11(17):6198-6204.
[27]王红建,史成章.Ezrin、FAK及E-cadherin在大肠癌组织中的表达及其临床意义.世界华人消化杂志 2007;15(6):591-595.
[28]Bussemakers MJG,Bokhoven AV,Mees SGM,et al.Molecular cloning and characterization of the human E-cadherin cDNA[J].Mol Biol Rep,1993,17:123.
[29]Raym E,Mehra R,Sandlerh M,et al.E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes[J].Juro,2006,176(41):1409-1414.
[30]Chenh C,Chur Y,Hsup N,et al.Loss of E-cadherin expression correlates with poor differentiation and invasion into adjacent organs in gastric adenocarcinomas[J].Cancer Lett,2003,201(1):97-106.
[31]Nuclear accumulation of E-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas.Elston MS,Gill AJ,Conaglen JV,Clarkson A,Cook RJ,Little NS,Robinson BG,Clifton-Bligh RJ,McDonald KL.J Clin Endocrinol Metab.2009,94(4).1436-1442.
[32]Shnayder Y,Kuriaknase Ma,Yee H,et al.Adherin molecules as prognostic factors in nasophryngeal carcinoma[J]Larngoscope,2001,111(10):1842-1846.
[33]李琼,吴明富,宋安萍,等.浸润性乳腺导管癌组织中Ezrin和钙粘素E的表达与淋巴结转移的关系[J].癌症,2006,25(3):363-66.
[34]Hiscox S,Jiang W G.Ezrin regulates cell-cell and cellmatrixadhesion,a possible role with Ecadherin/b-catenin[J].JCell Sci,1999,112(18):3081-3090.
[35]Pujuguent P,Del Maestro L,Gautreau A,et al.Ezrin regulates E-Cadherin-dependent adherens junction assembly through Racl activation[J].Mol Biol Cell,2003,14(5):2181-2191.
[36]Xu Y,Yu Q.E-cadherin negatively regulatesCD44-hyaluronan interaction and CD44-mediated tumor invasion and branchingmorphogenesis[J].J BiolChem,2003,278(10):8661-8668.
[1]Folkman J.What is the evidence that tumors are angiogenesis denpendent?[J].Natl Cancer Inst,1990,8(2):4-6.
[2]Tsuji A,Wakisaka N,Kondo S,etal.Induction of receptor for advanced glycation end products by EBV latent membrane protein 1 and its correlation with angiogenesis and cervical lymph node metastasis in nasopharyngeal carcinoma.Clin Cancer Res.2008 Sep l;14(17) 89:2833-2842.
[3]黄国森,涂青松等.鼻咽癌的血管生成及临床意义.中国耳鼻咽喉颅底外科杂志,2004,010(01):
[4]Nico B,Benagiano V,etal.Evaluation of microvascular density in tumors:pro and contra.Ribatti D.Histol Histopathol.2008 May;23(5):601-7.
[5]IonescuDN,SasatomiE,CieplyK,etal.Protein expression and gene amplification of epidermal growth factor receptorin thymomas[J].Cancer,2005,103(3):630-636.
[6]李智,林素暇,梁惠珍等.巨噬细胞移动抑制因子与鼻咽癌微血管生成和淋巴结转移的关系[J].中山大学学报医学科学版,2005,26(1):24-28.
[7]Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.Figueira RC,Gomes LR,Neto JS,Silva FC,Silva ID,Sogayar MC.BMC Cancer.2009 Jan 14;9:20.
[8]王双乐,江远仕,黄河澄等.上皮钙黏附蛋白、黏附分子CD44H、基质金属蛋白酶-3、肿瘤转移抑制基因nm23H1和血管内皮生长因子的表达与鼻咽癌转移的关系[J].临床耳鼻咽喉科杂志,2004,18(8):470-472.
[9]Mazar AP.Urokinase plasminogen activator receptor choreographs multiple ligand interactions:implications for tumor progression and therapy.Clin Cancer Res.2008 Sep 15;14(18):5649-55.
[10]Bussemakers MJG,Bokhoven AV,Mees SGM,et al.Molecular cloning and characterization of the human E-cadherin cDNA[J].Mol Biol Rep,1993,17:123.
[11]CharalabopoulosK,GogaliA,DalavagaY,etal.The clinical significance of soluble E-cadherin in on small cell lung cancer(J).ExpOncol,2006,28(1):83.
[12]Li Z,Ren Y,Lin SX,Liang YJ,etal Association of E-cadherin and betacatenin with metastasis in nasopharyngeal carcinoma..Chin Med J(Engl).2004Aug;117(8):1232-9.
[13]Yang X,Liu M,Han E,Guo H,et al.Expression and implication of CD44 and nm23-H1 proteins in laryngeal carcinoma..Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.2008 Feb;22(3):119-121.
[14]SUBRAMANIANC,COTTERMA,ROBERTSONES.Epstein-Barr virus unclear protein EBNA-3Cin-teracts with the human metastatic suppress or nm23-H1:amon lecular link to cancer metastasis[J].NaMed,2001,7:350-355.
[15]LiuY.The human hepatocyte growth factor receptor gene:complete structural、organization and promoter characterization(J) Gene,1998,215(1):159.
[16]刘崇梅,罗泊涛,李德祥.鼻咽癌组织中c-met基因表达及其与癌侵袭和转移的关系:实用癌症杂志,2004,19(3),02.
[17]SasakiH,YukiueH,KobayashiY,etal.Expression of the MTA1 mRNA in thymoma patients.CancerLett,2001,174(2):159-163.
[18]Hamatsu T,Rikimaru T,Yamashita Y,et al.The role ofMTA1 gene expression in human hepatocellμlar carcinoma.Oncol Rep,2003,10(3):599-604.
[19]Ma J,Zhou J,Fan S,et al.Role of a novel EGF-like domaincontaining gene NGX6 in cell adhesion modulation in nasopharyngeal carcinoma cells.Carcinogenesis,2005,26(2):281-291
[20]Peng S,Fan S,Li X,et al.The expression of ezrin in NPC and its interaction with NGX6,a novel candidate suppressor.Cancer Sci,2007,98(3):341-349
[21]罗元,赵惠柳等.Tiam-1mRNA及其蛋白的表达与鼻咽癌浸润转移的关系.临床与实验病理学杂志,2007,42(03),5
[22]张文玲等鼻咽癌分子标志物研究.生物化学与生物物理进展.Progress in Biochemistry and Biophysics 2008,35(1):7-13
[23]Horikawa T,Sheen T S,Takeshita H,et al.Induction of c-Metproto-oncogene by Epstein-Barr virus latent membrane protein-land the correlation with cervical lymph node metastasis of naso-pharyngeal carcinoma[J].Am J Pathol,2001,159(1):27-33.
[1]崔念基,卢泰祥,邓小武等.第二届全国鼻咽癌放射治疗学会会议纪要[J].中华放射肿瘤学杂志,2003;12(1):71-72.
[2]Leibel SA,Kutcher GJ,Harrison LB,et al.Improved dose in distri-butions for 3D conformal boosttreatments in carcinoma ofthe nasophar-ynx[J].Int J Radiat Oncol Biol Phys,1991;20(4):823-833
[3]Gerber DE,Chan TA.Recent advances in radiation therapy.Am Fam Physician.2008 Dec 1;78(11):1254-62.
[4]Wolden SL,ChenWC,PfisterDG;et al.Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer:update of the Memorial Sloan-Kettering experience[J].IntJRadiatOncolBiolPhys,2006,64(1):57-62.
[5]赵充,韩非,卢丽霞,等.调强适形放射治疗对局部晚期鼻咽癌的临床疗效[J].癌症,2004,23(11):1532-1537.
[6]Nakamura T,Kodaira T,etal.Tachibana H Chemoradiotherapy for locally recurrent nasopharyngeal carcinoma:treatment outcome and prognostic factors.Jpn J Clin Oncol.2008 Dec;38(12):803-809.
[7]Baujat B,Audry H,Bourhis J,et al.Chemotherapy in locoregion-ally advanced nasopharyngeal carcinoma:an individual patientdata meta-analysis of eight randomized trials and 1753 patients[J].Int J Radiat Oncol Biol Phys,2006,64(1):47-56.
[8]苏勇等.实用鼻咽癌放射治疗学[M].北京:北京大学医学出版社,2003;434-445.
[9]Zidan J,Kuten A,Robinson E.Intensive short coursechemotherapy followes by radiotherapy of locally advancednasopharyngeal carcinoma[J].cancer,1996;77:1973.
[10]马骏,麦海强,洪明晃等.中晚期鼻咽癌新辅助化疗联合放疗前瞻性临床试验的长期结果[J].癌症,2001;20(5):505-510.
[11]Liu MZ,He LR,Lu TX,Chen YY,etal.Effect of hypoxic radiosensitizer sodium glycididazole on long-term result of radiotherapy for nasopharyngeal carcinoma.Zhonghua Zhong Liu Za Zhi.2006 Dec;28(12):932-7.
[12]孙燕,周际昌.临床肿瘤内科手册.第4版.北京:人民卫生出版社,2003.494.
[13]Chan ATC.Head and neck cancer:treatment of nasopharyngealcancer[J].Ann Oncol,2005,16(Suppl 2):265-268.
[14]Koichi Isobe,Hiroyuki Kawakami,Takashi Uno,et al.Concur-rent chemoradiotherapy for locoregionally advanced nasopharyn-geal carcinoma:is Intergroup Study 0099 feasible in Japanese pa-tients[J]Jpn J Clin Oncol,2003,33(10):497-500.
[15]BonnerJA,HarariPM,GiraltJ,eta.lRadiotherapypluscetu-imabforsquamouscellcarci nomaoftheheadandneck[J].NewEnglJMed,2006,354(6):567-578.
[16]叶柯,陈奎生.适形调强放射治疗局部复发鼻咽癌近期疗效分析.肿瘤基础与临床 2007,20(6):493-494
[17]赵充,卢泰祥,韩非,等.139例鼻咽癌调强放疗的临床研究[J].中华放射肿瘤学杂志,2006,15(1):1-6.
[18]Wei WI.Salvage surgery for recurrent primary nasopharyngeal carcinoma.Crit Rev Oncol Hematol,2000,33(2):91-98.
[19]洪明晃,闵华庆.鼻咽癌的分层综合治疗[J].中国肿瘤,1997,6(7):16-17.
[2]Bussemakers MJG,Bokhoven AV,Mees SGM,et al.Molecular cloning and characterization of the human E-cadherin cDNA[J].Mol Biol Rep,1993,17:123.
[3]Chou J,Lin YC,et,Kim J,Nasopharyngeal carcinoma—review of the molecular mechanisms of tumorigenesis.Head Neck.2008 Jul;30(7):946-63.
[4]Musial J,Sporny S,Nowicki A.Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer.Pol J Pathol.2007;58(4):235-243.
[5]YuY,Khan J,KhannaC,eta.l Expression profiling identifies the cytoskeletal organizer ezrin and the developmental hemeoprotein sixl as key metastatic regulators[J].NatMed,2004,10:175-181.
[6]MeClatehey Al.Merlin and ERM proteins:unappreciated roles in cancer development?Nat Rev Cancer 2003;3:877-883.
[7]HannaC,WanX,BoseS,CassadayR,Olomu0,MendozaA,YeungC,GorliekR,HewittSM,HelmanLJ.The membranecytoskeleton linker ezrin is necessary for osteosarcozna metastasis.Nat Med2004;10:182-186.
[8]Bruce B,Khanna G,et at,Expression of the cytoskeleton linker protein ezrin in human cancers.Clin Exp Metastasis.2007;24(2):69-78.
[9]Slater M,Cooper M,Murphy CR.The cytoskeletal proteins alpha-actinin,Ezrin,and talin are De-expressed in endometriosis and endometrioid carcinoma compared with normal uterine epithelium.Appl Immunohistochem Mol Morphol.2007;15(2):170-174.
[10]ValdrnanA,Fangx,PangST,NilssonB,EkmanP,EgevadL.Ezrin expression in prostate cancer and begian prostatic tissue.Eur Urol 2005;48:852-857.
[11]Federici C,Brambilla D,et,at,Pleiotropic function of ezrin in human metastatic melanomas.Int J Cancer,2009;124(12):2804-2812.
[12] Li Q, Wu M, et,Ezrin silencing by small hairpin RNA reverses metastatic behaviors of human breast cancer cells. Cancer Lett. 2008 ,261(1):55-63.
[13] Bornman D M, Mathew S, Alsrnhe J, et al. Methylation of the E-cadherin gene bladder neop lasia and in normal u rothelial expression from elderly individuals [J].Am J Pathol,2001,159(3):831-835.
[14] Gonzalea M A, Pinder S E, Wencyk P M, et al. An immunohistochemical examination of the expression of Ecadherin,aand p7y-catenins, and a2 and (31 integrins in invasive breast cancer [ J]. J Pathol, 1999, 187 ( 5): 523 -529.
[15] Vaheri A, Carpen O, Heiska L, et al. The ezrin protein family:membrane-cytoskeleton intevactions and disease associations [J].Curr Opin Cell Biol, 1997, 9(5): 659- 666.
[16] Smith W J, Nassar N, Bretscher A, et al. Andrew Karplus. Structure of the Active N- terminal Domain of Ezrin[J]. J Biol Chem, 2003, 278(7): 4949- 4956.
[17] Osawa H, Smith CA,et,at, The role of the membrane cytoskeleton crosslinker ezrin in medulloblastoma cells.Neuro Oncol. 2008,10(2): 175- 256.
[18] Poullet P, Gautreau A, Kadare G, et al. Ezrin Interacts with Focal Adhesion Kinase and Induces Its Activation Independently of Cellmatrix Adhesion[J]. J Biol Chen, 2001, 276 (40): 37686- 37691.
[19] Yu Y, Khan J, Khanna C, et al. Expression profilingidentifies thecytoskeletal organizer ezrin and thedevelopmental homeoprotein Six las key metastatic regulators [J]. Nat Med, 2004,10(2): 175- 256.
[20] Thorne R F, Legg J W, Isacke C M. The role of the CD44 transmembrane and cytoplasmic domains in co- ordinated adhesive and signaling Events[J]. JCell Sci, 2004,117(3): 373-380.
[21] Fievet BT, Gautreau A, Roy C, et al. Phosphoinositide binding and phosphorylation act sequentially in the activation mechanism of ezrin[J]. J Cell Biol, 2004, 164(5): 653-659.
[22] Martin T A, Harrison G, Mansel R E, et al. The role of the CD44/ezrin complex in cancer metastasis [J]. Crit Rev Oncol Hematol,2003,46(2): 165- 186.
[23] McClatchey A I. Merlin and ERM proteins: unappreciatedroles in cancer development[J].Cancer,2003,3(11):877-884.
[24]Federici C,Brambilla D,et,at,Pleiotropic function of ezrin in human metastatic melanomas.Int J Cancer.2009 Jun 15;124(12):2804-12.
[25]Kobel M,Langhammer T,Huttelmaier S,et al.Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas[J].Mod Pathol,2006,19(4):581-587.
[26]Weng WH,Ahlen J,Astrom K,et al.Prognostic impact of immunohistochemical expression of ezrin in highly malignant softtissue sarcomas[J].Clin Cancer Res,2005,11(17):6198-6204.
[27]王红建,史成章.Ezrin、FAK及E-cadherin在大肠癌组织中的表达及其临床意义.世界华人消化杂志 2007;15(6):591-595.
[28]Bussemakers MJG,Bokhoven AV,Mees SGM,et al.Molecular cloning and characterization of the human E-cadherin cDNA[J].Mol Biol Rep,1993,17:123.
[29]Raym E,Mehra R,Sandlerh M,et al.E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes[J].Juro,2006,176(41):1409-1414.
[30]Chenh C,Chur Y,Hsup N,et al.Loss of E-cadherin expression correlates with poor differentiation and invasion into adjacent organs in gastric adenocarcinomas[J].Cancer Lett,2003,201(1):97-106.
[31]Nuclear accumulation of E-cadherin correlates with loss of cytoplasmic membrane staining and invasion in pituitary adenomas.Elston MS,Gill AJ,Conaglen JV,Clarkson A,Cook RJ,Little NS,Robinson BG,Clifton-Bligh RJ,McDonald KL.J Clin Endocrinol Metab.2009,94(4).1436-1442.
[32]Shnayder Y,Kuriaknase Ma,Yee H,et al.Adherin molecules as prognostic factors in nasophryngeal carcinoma[J]Larngoscope,2001,111(10):1842-1846.
[33]李琼,吴明富,宋安萍,等.浸润性乳腺导管癌组织中Ezrin和钙粘素E的表达与淋巴结转移的关系[J].癌症,2006,25(3):363-66.
[34]Hiscox S,Jiang W G.Ezrin regulates cell-cell and cellmatrixadhesion,a possible role with Ecadherin/b-catenin[J].JCell Sci,1999,112(18):3081-3090.
[35]Pujuguent P,Del Maestro L,Gautreau A,et al.Ezrin regulates E-Cadherin-dependent adherens junction assembly through Racl activation[J].Mol Biol Cell,2003,14(5):2181-2191.
[36]Xu Y,Yu Q.E-cadherin negatively regulatesCD44-hyaluronan interaction and CD44-mediated tumor invasion and branchingmorphogenesis[J].J BiolChem,2003,278(10):8661-8668.
[1]Folkman J.What is the evidence that tumors are angiogenesis denpendent?[J].Natl Cancer Inst,1990,8(2):4-6.
[2]Tsuji A,Wakisaka N,Kondo S,etal.Induction of receptor for advanced glycation end products by EBV latent membrane protein 1 and its correlation with angiogenesis and cervical lymph node metastasis in nasopharyngeal carcinoma.Clin Cancer Res.2008 Sep l;14(17) 89:2833-2842.
[3]黄国森,涂青松等.鼻咽癌的血管生成及临床意义.中国耳鼻咽喉颅底外科杂志,2004,010(01):
[4]Nico B,Benagiano V,etal.Evaluation of microvascular density in tumors:pro and contra.Ribatti D.Histol Histopathol.2008 May;23(5):601-7.
[5]IonescuDN,SasatomiE,CieplyK,etal.Protein expression and gene amplification of epidermal growth factor receptorin thymomas[J].Cancer,2005,103(3):630-636.
[6]李智,林素暇,梁惠珍等.巨噬细胞移动抑制因子与鼻咽癌微血管生成和淋巴结转移的关系[J].中山大学学报医学科学版,2005,26(1):24-28.
[7]Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential.Figueira RC,Gomes LR,Neto JS,Silva FC,Silva ID,Sogayar MC.BMC Cancer.2009 Jan 14;9:20.
[8]王双乐,江远仕,黄河澄等.上皮钙黏附蛋白、黏附分子CD44H、基质金属蛋白酶-3、肿瘤转移抑制基因nm23H1和血管内皮生长因子的表达与鼻咽癌转移的关系[J].临床耳鼻咽喉科杂志,2004,18(8):470-472.
[9]Mazar AP.Urokinase plasminogen activator receptor choreographs multiple ligand interactions:implications for tumor progression and therapy.Clin Cancer Res.2008 Sep 15;14(18):5649-55.
[10]Bussemakers MJG,Bokhoven AV,Mees SGM,et al.Molecular cloning and characterization of the human E-cadherin cDNA[J].Mol Biol Rep,1993,17:123.
[11]CharalabopoulosK,GogaliA,DalavagaY,etal.The clinical significance of soluble E-cadherin in on small cell lung cancer(J).ExpOncol,2006,28(1):83.
[12]Li Z,Ren Y,Lin SX,Liang YJ,etal Association of E-cadherin and betacatenin with metastasis in nasopharyngeal carcinoma..Chin Med J(Engl).2004Aug;117(8):1232-9.
[13]Yang X,Liu M,Han E,Guo H,et al.Expression and implication of CD44 and nm23-H1 proteins in laryngeal carcinoma..Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.2008 Feb;22(3):119-121.
[14]SUBRAMANIANC,COTTERMA,ROBERTSONES.Epstein-Barr virus unclear protein EBNA-3Cin-teracts with the human metastatic suppress or nm23-H1:amon lecular link to cancer metastasis[J].NaMed,2001,7:350-355.
[15]LiuY.The human hepatocyte growth factor receptor gene:complete structural、organization and promoter characterization(J) Gene,1998,215(1):159.
[16]刘崇梅,罗泊涛,李德祥.鼻咽癌组织中c-met基因表达及其与癌侵袭和转移的关系:实用癌症杂志,2004,19(3),02.
[17]SasakiH,YukiueH,KobayashiY,etal.Expression of the MTA1 mRNA in thymoma patients.CancerLett,2001,174(2):159-163.
[18]Hamatsu T,Rikimaru T,Yamashita Y,et al.The role ofMTA1 gene expression in human hepatocellμlar carcinoma.Oncol Rep,2003,10(3):599-604.
[19]Ma J,Zhou J,Fan S,et al.Role of a novel EGF-like domaincontaining gene NGX6 in cell adhesion modulation in nasopharyngeal carcinoma cells.Carcinogenesis,2005,26(2):281-291
[20]Peng S,Fan S,Li X,et al.The expression of ezrin in NPC and its interaction with NGX6,a novel candidate suppressor.Cancer Sci,2007,98(3):341-349
[21]罗元,赵惠柳等.Tiam-1mRNA及其蛋白的表达与鼻咽癌浸润转移的关系.临床与实验病理学杂志,2007,42(03),5
[22]张文玲等鼻咽癌分子标志物研究.生物化学与生物物理进展.Progress in Biochemistry and Biophysics 2008,35(1):7-13
[23]Horikawa T,Sheen T S,Takeshita H,et al.Induction of c-Metproto-oncogene by Epstein-Barr virus latent membrane protein-land the correlation with cervical lymph node metastasis of naso-pharyngeal carcinoma[J].Am J Pathol,2001,159(1):27-33.
[1]崔念基,卢泰祥,邓小武等.第二届全国鼻咽癌放射治疗学会会议纪要[J].中华放射肿瘤学杂志,2003;12(1):71-72.
[2]Leibel SA,Kutcher GJ,Harrison LB,et al.Improved dose in distri-butions for 3D conformal boosttreatments in carcinoma ofthe nasophar-ynx[J].Int J Radiat Oncol Biol Phys,1991;20(4):823-833
[3]Gerber DE,Chan TA.Recent advances in radiation therapy.Am Fam Physician.2008 Dec 1;78(11):1254-62.
[4]Wolden SL,ChenWC,PfisterDG;et al.Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer:update of the Memorial Sloan-Kettering experience[J].IntJRadiatOncolBiolPhys,2006,64(1):57-62.
[5]赵充,韩非,卢丽霞,等.调强适形放射治疗对局部晚期鼻咽癌的临床疗效[J].癌症,2004,23(11):1532-1537.
[6]Nakamura T,Kodaira T,etal.Tachibana H Chemoradiotherapy for locally recurrent nasopharyngeal carcinoma:treatment outcome and prognostic factors.Jpn J Clin Oncol.2008 Dec;38(12):803-809.
[7]Baujat B,Audry H,Bourhis J,et al.Chemotherapy in locoregion-ally advanced nasopharyngeal carcinoma:an individual patientdata meta-analysis of eight randomized trials and 1753 patients[J].Int J Radiat Oncol Biol Phys,2006,64(1):47-56.
[8]苏勇等.实用鼻咽癌放射治疗学[M].北京:北京大学医学出版社,2003;434-445.
[9]Zidan J,Kuten A,Robinson E.Intensive short coursechemotherapy followes by radiotherapy of locally advancednasopharyngeal carcinoma[J].cancer,1996;77:1973.
[10]马骏,麦海强,洪明晃等.中晚期鼻咽癌新辅助化疗联合放疗前瞻性临床试验的长期结果[J].癌症,2001;20(5):505-510.
[11]Liu MZ,He LR,Lu TX,Chen YY,etal.Effect of hypoxic radiosensitizer sodium glycididazole on long-term result of radiotherapy for nasopharyngeal carcinoma.Zhonghua Zhong Liu Za Zhi.2006 Dec;28(12):932-7.
[12]孙燕,周际昌.临床肿瘤内科手册.第4版.北京:人民卫生出版社,2003.494.
[13]Chan ATC.Head and neck cancer:treatment of nasopharyngealcancer[J].Ann Oncol,2005,16(Suppl 2):265-268.
[14]Koichi Isobe,Hiroyuki Kawakami,Takashi Uno,et al.Concur-rent chemoradiotherapy for locoregionally advanced nasopharyn-geal carcinoma:is Intergroup Study 0099 feasible in Japanese pa-tients[J]Jpn J Clin Oncol,2003,33(10):497-500.
[15]BonnerJA,HarariPM,GiraltJ,eta.lRadiotherapypluscetu-imabforsquamouscellcarci nomaoftheheadandneck[J].NewEnglJMed,2006,354(6):567-578.
[16]叶柯,陈奎生.适形调强放射治疗局部复发鼻咽癌近期疗效分析.肿瘤基础与临床 2007,20(6):493-494
[17]赵充,卢泰祥,韩非,等.139例鼻咽癌调强放疗的临床研究[J].中华放射肿瘤学杂志,2006,15(1):1-6.
[18]Wei WI.Salvage surgery for recurrent primary nasopharyngeal carcinoma.Crit Rev Oncol Hematol,2000,33(2):91-98.
[19]洪明晃,闵华庆.鼻咽癌的分层综合治疗[J].中国肿瘤,1997,6(7):16-17.